# Bioventus Inc. Class A Common Stock (NASDAQ:BVS)

> Bioventus is a global leader of innovations for active healing and surgical orthobiologics with a comprehensive portfolio of clinically efficacious and cost-effective solutions for patients, physicians and payers.

## Key facts

- **Shares outstanding:** 35,038,052
- **Leadership:** Robert Claypoole (Chief Executive Officer, Mr. Claypoole joins Bioventus from Mölnlycke Health Care, where he served as Executive Vice President of Wound Care, responsible for a $1.2 billion business. He has held various leadership roles at Medtronic and Covidien, focusing on growth and turnaround strategies.), Mark Singleton (Senior Vice President and Chief Financial Officer, Mr. Singleton has over two decades of experience in operational finance and mergers & acquisitions, previously serving as Vice President of Finance at Teleflex.), Katrina Church (Chief Compliance Officer), Anthony D’Adamio (Senior Vice President and General Counsel), Helen Leupold (Senior Vice President, Chief Human Resources Officer), Mike Crowe (Senior Vice President, Operations), Dave Venner (Senior Vice President, General Manager, Surgical), Megan Rosengarten (SVP, General Manager, Peripheral Nerve Stimulation), Kellie Stefaniak (Vice President of Global Regulatory and Quality), Anthony Doyle (General Manager, Pain Treatment & Restorative Therapies), Sharath Bhat (Vice President/General Manager, EMEA APAC)

_Verified data last updated: 2026-08-14_

## Recent filings

- 2026-08-05 — other — [bvs_2026-08-05_10-40-11.pdf](https://ai-chat-dev-red.vercel.app/bvs/preview/109650?documentId=109650)
- 2026-07-27 — other — [bvs_2026-07-27_19-25-25.pdf](https://ai-chat-dev-red.vercel.app/bvs/preview/103169?documentId=103169)
- 2026-06-04 — other — [bvs_2026-06-04_20-06-35.pdf](https://ai-chat-dev-red.vercel.app/bvs/preview/103170?documentId=103170)
- 2026-06-04 — other — [bvs_2026-06-04_19-48-01.pdf](https://ai-chat-dev-red.vercel.app/bvs/preview/103171?documentId=103171)
- 2026-06-04 — other — [bvs_2026-06-04_19-47-48.pdf](https://ai-chat-dev-red.vercel.app/bvs/preview/103172?documentId=103172)
- 2026-06-04 — other — [bvs_2026-06-04_19-47-35.pdf](https://ai-chat-dev-red.vercel.app/bvs/preview/103173?documentId=103173)
- 2026-06-04 — other — [bvs_2026-06-04_19-47-18.pdf](https://ai-chat-dev-red.vercel.app/bvs/preview/103174?documentId=103174)
- 2026-06-04 — other — [bvs_2026-06-04_19-47-04.pdf](https://ai-chat-dev-red.vercel.app/bvs/preview/103175?documentId=103175)

## Live AI chat

- https://ai-chat-dev-red.vercel.app/bvs/chat
- Investor website: https://bioventus.com/